Initiate the pivotal Phase III clinical trial for lanifibranor
Delivered after the deadline (70 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 8 Sep 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Inventiva plans to initiate the trial in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company announced the initiation of the pivotal Phase III clinical trial for lanifibranor on September 8, 2021, which occurred after the first half of 2021 deadline.
-
A Inventiva S.A. 20-F filed 2022-03-11
“On September 8, 2021, the Company announced the initiation of its NATiV3 Phase III clinical trial evaluating lanifibranor for the treatment of NASH.” ✓ confirmed on the page
Market reaction: the shares moved -6.6% against the S&P 500 over the three sessions around the disclosure (10 Mar 2022 to 15 Mar 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- pivotal Phase III clinical trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Inventiva S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IVA-021037 · Corrections policy